Cadonilimab lenvatinib clinical trials
Cadonilimab lenvatinib is named as an intervention in 51 current clinical trials in our China register. 31 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Akeso (17). The most-studied condition is Cervical Cancer.
Patient leaflets for Cadonilimab lenvatinib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Cadonilimab lenvatinib
51 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Cadonilimab lenvatinib
66 conditionsAll 66 conditions
| Condition (as registered) | Trials |
|---|---|
| Cervical Cancer | 4 |
| Hepatocellular Carcinoma | 4 |
| Gastroesophageal Junction Adenocarcinoma | 2 |
| Non-small Cell Lung Cancer | 2 |
| Gastric Cancer | 2 |
| Colorectal Cancer | 2 |
| Recurrent or Metastatic Nasopharyngeal Carcinoma | 1 |
| Locally Advanced Cervical Carcinoma | 1 |
| Cadonilimab and Lenvatinib | 1 |
| Advanced Soft-tissue Sarcoma | 1 |
| Pancreatic Cancer | 1 |
| Head and Neck Squamous Cell Carcinoma | 1 |
| Gastric Adenocarcinoma | 1 |
| Unresectable, Non-metastatic Hepatocellular Carcinoma | 1 |
| NSCLC | 1 |
| Locally Advanced Lung Carcinoma | 1 |
| Advanced Non-small-cell Lung Cancer | 1 |
| Breast Cancer | 1 |
| Resectable Colon Cancer | 1 |
| MSI-H/dMMR Colorectal Cancer | 1 |
| Melanoma | 1 |
| Mucosal Melanoma | 1 |
| Metastatic Melanoma | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Immune Checkpoint Inhibitor | 1 |
| Radiotherapy | 1 |
| Chemotherapy | 1 |
| Locally Advanced or Metastatic NSCLC | 1 |
| HER2-positive Gastric Cancer | 1 |
| Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy | 1 |
| Triple Negative Breast Cancer | 1 |
| Esophagus Cancer | 1 |
| MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer | 1 |
| Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 1 |
| Esophagogastric Junction Cancer | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Endometrial Cancer | 1 |
| Endometrial Adenocarcinoma | 1 |
| Healthy Male Adults Participants | 1 |
| Renal Cell Carcinoma | 1 |
| First-line Treatment | 1 |
| Non Clear Cell Renal Cell Carcinoma | 1 |
| Sarcomatoid Renal Cell Carcinoma | 1 |
| SCLC, Extensive Stage | 1 |
| Gastric and Gastroesophageal Junction Adenocarcinoma | 1 |
| Advanced Solid Tumor | 1 |
| Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 1 |
| Colon Rectal Cancer Adenocarcinoma | 1 |
| Peritoneal (Metastatic) Cancer | 1 |
| Second-line Treatment | 1 |
| Radiation Therapy | 1 |
| Metastatic HER2 Positive Gastroesophageal Junction Cancer | 1 |
| NSCLC (Non-small Cell Lung Cancer) | 1 |
| Leptomeningeal Metastasis | 1 |
| Endometrial Neoplasms | 1 |
| Neoplasm Recurrence, Local | 1 |
| Neoplasm Metastasis | 1 |
| Neoadjuvant Chemoimmunotherapy | 1 |
| Radical Hysterectomy | 1 |
| Extrafascial Hysterectomy | 1 |
| Hepatocellular Carcinoma (HCC) | 1 |
| Cervical Adenocarcinoma | 1 |
| Gastric-type Endocervical Adenocarcinoma | 1 |
| Recurrent Ovarian Cancer | 1 |
| Neoadjuvant Immunotherapy | 1 |
| Fertility-sparing Surgery | 1 |
Sponsors
lead sponsor per trial+ 13 more sponsors in the trial list above.
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 51 | 31 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Cadonilimab lenvatinib trials
How many clinical trials are testing Cadonilimab lenvatinib?
51 current trials in our China register name Cadonilimab lenvatinib (also registered as AK104) as a drug or biological intervention, as of the registry sync on 14 October 2026. Completed and withdrawn studies are not counted.
Are Cadonilimab lenvatinib trials recruiting patients?
Yes. 31 of the 51 trials are recruiting: 31 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Cadonilimab lenvatinib clinical trials?
Akeso (17), Sun Yat-sen University (5), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) and Harbin Medical University (2), among 28 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cadonilimab lenvatinib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cadonilimab lenvatinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cadonilimab lenvatinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 14 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.